STAA

+ Watchlist + Portfolio

STAAR Surgical Company

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.66
52-Week Range: $15.59 – $35.87
Market Cap: $1.16B
P/E (TTM): 288.38
EPS (TTM): 0.08
Dividend Yield: —

Advanced Metrics

Price/Book: 3.26
PEG Ratio: 0.76
Return on Equity: 1.09%
Return on Assets: 5.65%
Gross Margin: 76.62%
Operating Margin: 10.89%
Profit Margin: 1.13%
Current Ratio: 4.67
Debt/Equity: 0.10
Total Debt: $35.94M
Free Cash Flow: $15.35M
Revenue Growth: 111.00%
Earnings Growth: —
Enterprise Value: $1.09B

STAA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$284.39M	$322.42M	$313.90M	$239.44M
Cost of Revenue	$61.01M	$69.76M	$74.32M	$57.02M
Gross Profit	$223.38M	$252.65M	$239.58M	$182.42M
Research & Development	$35.98M	$40.48M	$45.32M	$40.05M
Selling, General & Admin	$143.60M	$184.08M	$206.88M	$188.31M
Operating Expenses	$179.58M	$224.55M	$252.19M	$228.37M
Operating Income	$43.80M	$28.10M	-$12.61M	-$45.95M
EBITDA	$48.31M	$33.22M	-$5.72M	-$37.22M
Pretax Income	$45.55M	$33.70M	-$9.05M	-$82.26M
Income Tax	$5.89M	$12.35M	$11.16M	-$1.81M
Net Income	$39.66M	$21.35M	-$20.21M	-$80.45M
Diluted EPS	0.79	0.43	-0.41	-1.62
Diluted Shares	49.38M	49.43M	49.13M	49.57M

STAA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$86.48M	$183.04M	$144.16M	$153.15M
Receivables	$65.97M	$97.98M	$79.26M	$54.31M
Inventory	$24.16M	$35.13M	$43.30M	$55.50M
Current Assets	$311.72M	$365.27M	$367.94M	$311.55M
Total Assets	$418.82M	$488.69M	$509.52M	$451.68M
Current Liabilities	$51.72M	$65.04M	$70.31M	$68.50M
Total Debt	$31.04M	$35.83M	$38.74M	$38.35M
Total Liabilities	$82.71M	$102.74M	$112.19M	$107.49M
Retained Earnings	-$68.72M	-$47.37M	-$67.58M	-$148.02M
Shareholders' Equity	$336.11M	$385.95M	$397.33M	$344.18M
Working Capital	$260.01M	$300.23M	$297.63M	$243.04M

STAA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$35.72M	$14.59M	$15.72M	-$34.23M
Capital Expenditure	-$18.11M	-$18.19M	-$23.39M	-$5.82M
Free Cash Flow	$17.61M	-$3.59M	-$7.67M	-$40.05M
Depreciation & Amortisation	$4.51M	$5.12M	$6.89M	$8.73M
Stock-Based Compensation	$20.37M	$23.52M	$27.21M	$30.59M
Investing Cash Flow	-$156.38M	$74.35M	-$59.22M	$46.34M
Financing Cash Flow	$8.30M	$7.42M	$5.72M	-$4.55M
Share Repurchases	$0.00	-$2.10M	-$1.50M	-$7.98M
Net Change in Cash	-$112.36M	$96.36M	-$37.77M	$7.55M

STAA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$42.59M	$44.32M	$94.73M	$57.80M	$93.52M
Cost of Revenue	$14.58M	$11.52M	$16.86M	$14.06M	$24.66M
Gross Profit	$28.00M	$32.80M	$77.88M	$43.74M	$68.86M
Research & Development	$11.34M	$10.26M	$9.21M	$9.24M	$9.93M
Selling, General & Admin	$51.40M	$47.25M	$44.22M	$45.43M	$41.53M
Operating Expenses	$62.74M	$57.52M	$53.43M	$54.68M	$51.46M
Operating Income	-$34.74M	-$24.72M	$24.44M	-$10.94M	$17.40M
EBITDA	-$32.35M	-$22.79M	$26.44M	-$8.52M	$19.61M
Pretax Income	-$54.49M	-$25.91M	$18.79M	-$20.65M	$8.22M
Income Tax	-$275.00K	-$9.10M	$9.91M	-$2.34M	$3.01M
Net Income	-$54.21M	-$16.81M	$8.88M	-$18.31M	$5.21M
Diluted EPS	-1.10	-0.34	0.18	-0.37	0.10
Diluted Shares	49.34M	49.52M	50.55M	49.76M	50.90M

STAA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$173.11M	$167.13M	$176.16M	$153.15M	$131.86M
Receivables	$42.70M	$37.08M	$63.57M	$54.31M	$85.69M
Inventory	$48.14M	$53.11M	$53.30M	$55.50M	$49.78M
Current Assets	$326.50M	$292.79M	$321.21M	$311.55M	$312.40M
Total Assets	$457.36M	$437.78M	$456.36M	$451.68M	$451.12M
Current Liabilities	$68.36M	$59.23M	$61.64M	$68.50M	$60.99M
Total Debt	$36.68M	$40.52M	$39.12M	$38.35M	$37.29M
Total Liabilities	$107.39M	$101.21M	$102.58M	$107.49M	$98.75M
Retained Earnings	-$121.79M	-$138.60M	-$129.72M	-$148.02M	-$142.82M
Shareholders' Equity	$349.97M	$336.57M	$353.78M	$344.18M	$352.37M
Working Capital	$258.14M	$233.56M	$259.57M	$243.04M	$251.40M

STAA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.73M	-$27.25M	$2.67M	-$3.91M	-$21.70M
Capital Expenditure	-$1.47M	-$1.79M	-$883.00K	-$1.68M	-$443.00K
Free Cash Flow	-$7.20M	-$29.04M	$1.78M	-$5.59M	-$22.14M
Depreciation & Amortisation	$2.39M	$1.92M	$2.00M	$2.42M	$2.21M
Stock-Based Compensation	$6.01M	$7.80M	$8.16M	$8.61M	$4.82M
Investing Cash Flow	$35.35M	$25.12M	$5.28M	-$19.41M	$2.15M
Financing Cash Flow	-$948.00K	-$4.54M	$983.00K	-$50.00K	-$1.69M
Share Repurchases	-$1.28M	-$4.55M	-$1.98M	-$164.00K	-$1.87M
Net Change in Cash	$28.67M	-$6.67M	$8.93M	-$23.38M	-$21.24M

Market Snapshot

About

STAAR Surgical Company designs, develops, and manufactures implantable lenses for the eye. The company specializes in the EVO Implantable Collamer Lens for vision correction, offering an alternative to LASIK for patients with moderate to severe myopia.